BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).-MedSci.cn

BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).

Aggarwal, RR; Costin, D; Zhang, JS; Karsh, LI; Healey, DI; Linch, MD; Adurthi, S; Petrylak, DP; O'Neill, V; Monk, P

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务